A single centre experience in circumcision of haemophilia patients: Izmir protocol.
Haemophiliacs and their families consider that circumcision is a very important step to become a member of society and it is a social obligation for men in Turkey. Although bleeding risk is high, almost all haemophiliacs would like to be circumcised in Turkish society. The aim of this study was to evaluate our experience in circumcision of haemophilia patients and define efficacy, safety and complication rates of our protocol, called 'Izmir protocol'. In this study, we retrospectively reviewed medical records of 50 patients with haemophilia who underwent circumcision at our hospital according to Izmir protocol between 1996 and 2009. Oral tranexamic acid and fibrin glue were used in all children. One hour before the operation, first dose of factor concentrate was given. After reaching a plasma factor level of around 90-100%, the prepuce was incised circumferentially and excised using Gomco clamp or open technique under general anaesthesia. Intermittent injections of factor concentrate were given every 12 for 48 h. While the first two doses were given at higher amount to achieve or continue plasma factor level at 90-100%, in the last three doses, the aim was to maintain the plasma factor level at 50-60%. Forty-eight hours after the circumcision, patients were discharged. Three patients (6%) showed bleeding complication and all were resolved easily. All had at least one excuse from the protocol (Lower doses of factor concentrates was used in 2, tranexamic acid was not used in 2). Izmir protocol is safe, cheap and easy to carry out.
Yilmaz
D
D
Division of Hematology, Department of Pediatrics, Medical School, Ege University, Bornova, Izmir, Turkey. dyilmazk@yahoo.com
Akin
M
M
Ay
Y
Y
Balkan
C
C
Celik
A
A
Ergün
O
O
Kavakli
K
K
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D002944:Circumcision, Male / Q000009:adverse effects / Q000379:methods; D005164:Factor IX / Q000032:analysis / Q000627:therapeutic use; D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D002836:Hemophilia B / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D014148:Tranexamic Acid / Q000627:therapeutic use; D014421:Turkey
D000933:Antifibrinolytic Agents; D015718:Fibrin Tissue Adhesive; D014148:Tranexamic Acid; D005169:Factor VIII; D005164:Factor IX